Discrepancy Between Body Surface Area and Body Composition in Cancer

Abstract

Calculation of cytostatic dose is typically based on body surface area (BSA) regardless of body composition. The aim of this study was to assess the discrepancy between BSA and low fat-free mass (FFM) by investigating the prevalence of low FFM with regard to BSA in 630 cancer patients. First, BSA was calculated according to DuBois and DuBois. Patients were divided into 6 categories with respect to their BSA. Each BSA category was further divided into 3 groups according to FFM: low (<−1 SD of mean FFM), normal (−0.99 and 0.99 SD of mean FFM) or high (>1 SD of mean FFM), which was derived through bioelectric impedance analysis. FFM was reduced in 15.7% of patients, 69% had normal and 15.2% had high FFM. In patients with low FFM (i.e., more than-1 SD lower than the mean FFM within their BSA group), body mass index and fatigue were higher whereas functional status was reduced. Moreover, in the subcohort of patients receiving chemotherapy, absolute FFM [Hazard ratio (HR) = 0.970, P = 0.026] as well as the allocation to the low FFM group (HR = 1.644, P = 0.025) emerged as predictors of increased 1-yr mortality. In conclusion, there was a large discrepancy between FFM and BSA. Particularly women were affected by low FFM.

ACKNOWLEDGMENTS

The study was funded by Charité– University Medicine grant (nb. 10/46575) and was previously presented at the Annual Congress of ESPEN in Barcelona. Nicole Stobäus, Susanne Küpferling, Marie-Luise Lorenz, and Kristina Norman are members of the colorectal cancer center of the Charité– Universitätsmedizin Berlin. We thank Lindsey Otten, M.Sc. for correcting the English.